This rise in popularity was in turn accompanied by an increase in the number of reported cases of abuse. 4, 5 To better understand the burden of disease and spectrum of complications of buprenorphine abuse, we reviewed the medical records of hospitalized intravenous buprenorphine abusers at the National University Hospital, Singapore, from 2002 to 2005.
Using the keywords 'buprenorphine' and 'subutex', we searched the electronic database of our hospital to identify patients who had developed complications arising from active intravenous buprenorphine abuse. We reviewed the medical records of these patients to assess their complications and course of hospitalization, and to identify predictors of their clinical outcomes. We studied 51 patients (39 males, 12 females), mean AE SD age 35.14 AE 7.88 years. Infective complications such as cellulitis (39.2%), endocarditis (19.6%), and myositis/pyomyositis (11.8%), and non-infective complications such as withdrawal symptoms (13.7%), seizures (9.8%) and limb ischaemia (9.8%), were reported. Three patients (5.9%) required ventilatory support, and five (9.8%) were readmitted for further complications, but none died. Using multivariate analysis, we identified the presence of complications such as infective endocarditis, venous thrombosis and respiratory failure to significantly predict prolonged hospital stay amongst these patients (Table 1) .
We believe that only a multi-pronged approach can deliver the benefits of buprenorphine treatment seen in clinical trials and address the worldwide problem of opioid addiction. Potentially useful measures include observation and close monitoring of buprenorphine administration amongst opioiddependent patients, stringent control of buprenorphine prescription by trained physicians, newer combination agents to suppress buprenorphine abuse (e.g. buprenorphine/naloxone), adequate education for health-care workers and patients on the appropriate use of buprenorphine, and adequate law enforcement. doi:10.1093/qjmed/hcm027 
